Nonparametric estimation for cumulative duration of adverse events

Biometrical Journal

Volumn 54, Issue 1, 2012, Pages 61-74

  Wang, Jixian ^a   Quartey, George ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Adverse events; Benefit risk; Cumulative duration; Non Parametric estimation; Recurrent events

Indexed keywords

NUMERICAL METHODS; RISK PERCEPTION;

ADVERSE EVENTS; BENEFIT/RISK; CLINICAL TRIAL; CUMULATIVE DURATION; DRUG SAFETY; NON-PARAMETRIC ESTIMATIONS; OBSERVATIONAL STUDY; RECURRENT EVENTS; ROUTINE ANALYSIS; SAFETY ASSESSMENTS;

RISK ASSESSMENT;

EID: 84862910675     PISSN: 03233847     EISSN: 15214036     Source Type: Journal    
DOI: 10.1002/bimj.201000256     Document Type: Article

References (16)

1. Andersen, P. K. and Gill, R. D. (1982). Cox's regression model for counting processes: a large sample study. Annals of Statistics 10, 1100-1120.
2. Andersen, P. K. and Keiding, N. (2002). Multi-state models for event history analysis. Statistical Methods in Medical Research 11, 91-115.
3. Barker, C. (2010). Exploratory method for summarizing concomitant medication data - the mean cumulative function. Pharmaceutical Statistics 9, 331-336.
4. CIOMS Working Group IV (1998) Benefit-risk Balance for Marketed Drugs: Evaluating Safety Signals. CIOMS, Geneva.
5. Cook, R. J. and Lawless, J. F. (2002). Analysis of repeated events. Statistical Methods in Medical Research 11, 141-166.
6. Cook, R. J. and Lawless, J. F. (2007). The Statistical Analysis of Recurrent Events. Springer, New York.
7. Cook, R. J., Lawless, J. F., Lakhal-Chaieb, L. and Lee, K. (2009). Robust estimation of mean functions and treatment effects for recurrent events under event-dependent censoring and termination: application to skeletal complications in cancer metastatic to bone. Journal of the American Statistical Association 104, 60-75.
8. Couper, D. and Pepe, M. S. (1997). Modelling prevalence of a chronic condition: chronic graft-versus-host disease after bone marrow transplantation. Statistics in Medicine 16, 1551-1571.
9. Fine, J. P., Yan, J. and Kosorok, M. R. (2004). Temporal process regression. Biometrika 91, 683-703.
10. Fuchs, H., Borowitz, D., Christiansen, D., Morris, E., Nash, M., Ramsey, B., Rosenstein, B., Smith, A. and Wohl, M. (1994). Effect of aerosolized recombinant human dnase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. New England Journal of Medicine 331, 637-642.
11. Guo, J. J., Pandey, S., Doyle. J., Bian, B., Lis, Y. and Raisch, D. W. (2010) A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group. Value in Health 13, 657-666.
12. Klein, J. P. (2002). Multi-state models for bonemarrow transplantation studies. Statistical Methods in Medical Research 11, 117-139.
13. Lawless, J. F. and Nadeau, J. C. (1995). Some simple robust methods for the analysis of recurrent events. Technometrics 37, 158-168.
14. Lin, D. Y., Wei, L. J., Yang, I. and Ying, Z. (2000). Semiparametric regression for the mean and rate functions of recurrent events. Journal of the Royal Statistical Society: Series B 62, 711-731.
15. Siddiqui, O. (2009). Statistical methods to analyze adverse events data of randomized clinical trials. Journal of Biopharmaceutical Statistics 19, 889-899.
16. Yan, J. and Fine, J. P. (2008). Analysis of episodic data with application to recurrent pulmonary exacerbations in cystic fibrosis patients. Journal of the American Statistical Association 103, 498-510.